



Chikungunya epidemiology in U.S. territories and states with risk of transmission

Susan Hills MBBS MTH
CDC Lead, Chikungunya Vaccines Work Group
Arboviral Diseases Branch
Division of Vector-Borne Diseases
Fort Collins, Colorado

ACIP Meeting, June 26, 2024


Chikungunya

- Mosquito-borne disease
- Key vectors are *Aedes aegypti* and *Aedes albopictus* mosquitoes



Distribution and disease burden in endemic areas

- Typically tropical and subtropical regions
- Periodically causes large outbreaks
 - Often high attack rates
- Virus transmission usually highest during wet season



Countries and territories with current or past transmission of chikungunya virus

Clinical features of acute chikungunya virus infection

- Febrile illness with typically severe arthralgia, can be debilitating
- Other symptoms include headache, rash, myalgia, anorexia
- No anti-viral treatment available



Complications of chikungunya

- Rare serious complications (e.g., myocarditis, hepatitis, neurologic illness)
- Deaths rare and reported mostly in
 - Older adults, particularly those with comorbidities
 - Young infants infected perinatally or by mosquito bites



Infected: This man was so weakened by chikungunya that he needed a wheelchair. Adults over 50 and people with preexisting conditions are at higher risk of serious illness and require closer follow-up.



Infected at birth: This newborn girl contracted chikungunya from her mother during childbirth. Such babies require close follow-up and should not stay in breastfeeding.

Images from : <https://www.paho.org/en/topics/chikungunya>

Chronic arthralgia following chikungunya

- Acute symptoms usually resolve in 7–10 days
- Some patients have continuation or relapse of symptoms
- Ongoing arthralgia of variable severity possibly present in up to ~50% at 3 months and ~30% at 12 months



Puerto Rico

Puerto Rico

- Largest U.S territory
 - Population ~3.2 million persons
 - Area ~3,500 miles²
- Tropical climate
- *Aedes aegypti* present
- Dengue endemic



Data sources

- Data from passive and sentinel surveillance systems
- No single data source provides accurate and complete information
- Surveillance activities, reporting practices, and laboratory testing approaches changed during outbreak
 - When laboratory capacity exceeded, testing prioritized for certain groups
 - When number of suspected cases reached thousands per week, limitation on types of cases to be reported
- Key points
 - Numbers of cases often substantial underestimate of true cases
 - Data provide reasonable representation of actual disease epidemiology


Laboratory criteria for chikungunya cases

- **Confirmed cases:** detection of nucleic acid by RT-PCR
- **Probable cases:** IgM antibodies in serum or cerebrospinal fluid
- Chikungunya IgM antibodies can persist after acute infection
 - 13–18 months: 56% with IgM¹
 - 2–3 years: 11% with IgM²


Chikungunya emergence in the Caribbean

- Chikungunya emerged in 2013
 - First case reported in Saint Martin island in December
- Rapid increase in countries and territories reporting transmission
- In Puerto Rico, first laboratory-confirmed case in May 2014


Chikungunya cases reported by year and case status, Puerto Rico, 2014–2020



Chikungunya cases reported by year and case status, Puerto Rico, 2014–2020



Chikungunya cases by month of illness onset during two main outbreak years, 2014–2015



Chikungunya cases by sex, Puerto Rico, 2014–2020 (N=10,293)*

Sex	No.	(%)
Female	5,116	(52%)
Male	4,708	(48%)


*n=469 with unknown sex

Chikungunya cases by age group, Puerto Rico, 2014–2020 (N=10,293)*

Years	No. (%)
0–19	4,328 (42%)
20–39	2,055 (20%)
40–59	1,931 (19%)
≥60	1,865 (18%)

*n=114 with unknown age

Chikungunya cases by municipality, Puerto Rico, 2014–2020



Proportion of Puerto Rico population infected

- Household cluster survey among persons aged 1–50 years in one municipality in southern Puerto Rico in 2018–2019
 - **31% seroprevalence**¹
- Samples from blood donors aged ≥ 16 years collected in March 2015²
 - **23% seroprevalence**²
- Based on 30% seroprevalence rate, **~1 million** persons estimated to have been **infected** during outbreak
 - **~650,000–850,000 clinical cases**

1. 1,268 of 4,035 participants (Adams LE et al, PLoS NTD 2022); 2. 242 of 1,031 samples (Simmons G et al, Emerg Infect Dis 2016)

United States Virgin Islands (USVI)


Initial transmission of chikungunya in USVI

- First locally acquired case detected in early June 2014¹
- Initial transmission on Saint Thomas



Source: <https://ontheworldmap.com/virgin-islands-us/>

Epidemic curve of chikungunya cases* by island, USVI, 2014–2015 (N=637)



**Last laboratory-
positive case
February 2015**

Proportion of USVI population infected, 2014–2015

- 31% persons had evidence of past infection in seroprevalence survey approximately 1-year post-outbreak¹
- **~33,000** persons estimated to have been **infected** during outbreak
 - **~21,000–28,000 clinical cases during 8-month** outbreak period

1. Hennessey MJ et al, Am J Trop Med Hyg 2018

*Laboratory confirmed or probable

Other U.S. territories and freely associated states

Other U.S. territories

- **American Samoa¹**
 - Outbreak began June 2014
 - Unconfirmed information suggested ≥ 823 suspected cases
 - Unclear duration but no evidence of transmission by end of 2015
- **Guam and Commonwealth of the Northern Mariana Islands (CNMI)**
 - No cases reported

1. Roth A et al, Eurosurveillance 2014; ArboNET data

Freely associated states

- **Federated States of Micronesia (Yap State)¹**
 - Outbreak from Aug 2013–Aug 2014 with peak Oct–Dec 2013
 - 1,761 suspected cases reported
 - Attack rate of 155 clinical cases per 1,000 population, so ~15% population sought care for suspected illness
- **Marshall Islands²**
 - Outbreak began February 2015
 - Unclear duration and extent but unconfirmed information suggests >1,000 suspected cases
- **Palau**
 - No cases reported

Summary:


Chikungunya in U.S territories and affiliated states

- 3 territories and 2 affiliated states have had chikungunya outbreaks
- Outbreaks were explosive
- For Puerto Rico and USVI, ~30% of population was likely infected, with 20%–25% of the population having clinical illness mainly during a period ~6 months
- All outbreaks began 2013–2015
- No evidence of confirmed transmission since 2017 (Puerto Rico) or earlier in islands with smaller populations
- Timing of future transmission or outbreaks and likely pattern unknown


Locally-acquired cases in U.S states

Estimated potential range of *Aedes aegypti* and *Aedes albopictus* in the United States, 2017

Aedes aegypti



Aedes albopictus



Texas (N=1)

- One case in Cameron County
- Occurred in November 2015



Location of Cameron County, Texas

Acknowledgments

- Puerto Rico Department of Health
- Nicole Lindsey, Arboviral Diseases Branch
- Laura Adams, Dengue Branch
- Joshua Wong, Dengue Branch

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

